» Authors » Andreas Beilhack

Andreas Beilhack

Explore the profile of Andreas Beilhack including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 112
Citations 3792
Followers 0
Related Specialties
Top 10 Co-Authors
Published In
Affiliations
Soon will be listed here.
Recent Articles
1.
OBrien N, Mueller J, Broske A, Attig J, Osl F, Crisand C, et al.
MAbs . 2024 Dec; 17(1):2440578. PMID: 39686589
T cell bispecific antibodies (TCBs) are a promising new class of therapeutics for relapsed/refractory multiple myeloma. A frequently observed, yet incompletely understood effect of this treatment is the transient reduction...
2.
Moll G, Beilhack A
Front Immunol . 2024 Nov; 15:1516554. PMID: 39588366
No abstract available.
3.
Yu Y, Vogel T, Hirsch S, Groll J, Albrecht K, Beilhack A
Nanoscale . 2024 Nov; PMID: 39508295
We developed siRNA-loaded anionic liposomes, co-encapsulating low-dose amphotericin B, to enhance siRNA penetration through the fungal cell wall of . Targeting mRNAs of three key genes, these liposomes visibly inhibited...
4.
Gotz L, Rueckschloss U, Reimer A, Bommel H, Beilhack A, Ergun S, et al.
Aging Cell . 2024 Oct; 24(2):e14384. PMID: 39434463
Chronic inflammation with progressive age, called inflammaging, contributes to the pathogenesis of cardiovascular diseases. Previously, we have shown increased vascular expression of the Carcinoembryonic antigen-related cell adhesion molecule 1 (CEACAM1)...
5.
Gunther K, Nischang V, Cseresnyes Z, Kruger T, Sheta D, Abboud Z, et al.
Immunology . 2024 Sep; 173(4):748-767. PMID: 39268960
Gliotoxin (GT), a secondary metabolite and virulence factor of the fungal pathogen Aspergillus fumigatus, suppresses innate immunity and supports the suppression of host immune responses. Recently, we revealed that GT...
6.
Vogel T, Kohlmann S, Abboud Z, Thusek S, Fella F, Tessmar J, et al.
Macromol Biosci . 2024 Jun; 24(9):e2400082. PMID: 38850104
The ubiquitous mold Aspergillus fumigatus (A. fumigatus) is one of the main fungal pathogens causing invasive infections in immunocompromised humans. Conventional antifungal agents exhibit limited efficacy and often cause severe...
7.
Anany M, Haack S, Lang I, Dahlhoff J, Vargas J, Steinfatt T, et al.
Theranostics . 2024 Jan; 14(2):496-509. PMID: 38169605
Selective TNFR2 activation can be used to treat immune pathologies by activating and expanding regulatory T-cells (Tregs) but may also restore anti-tumour immunity by co-stimulating CD8 T-cells. Oligomerized TNFR2-specific TNF...
8.
Vargas J, Wagner J, Shaikh H, Lang I, Medler J, Anany M, et al.
Front Immunol . 2024 Jan; 14:1352525. PMID: 38164131
[This corrects the article DOI: 10.3389/fimmu.2022.888274.].
9.
McFleder R, Makhotkina A, Groh J, Keber U, Imdahl F, Pena Mosca J, et al.
Nat Commun . 2023 Nov; 14(1):7529. PMID: 37981650
Inflammation in the brain and gut is a critical component of several neurological diseases, such as Parkinson's disease (PD). One trigger of the immune system in PD is aggregation of...
10.
Bittrich M, Hetterich R, Solimando A, Krebs M, Loda S, Danhof S, et al.
Clin Exp Med . 2023 Oct; 23(8):5215-5226. PMID: 37805620
In addition to randomized clinical trials, consideration of Real-World Evidence is necessary for mirroring clinical reality. However, processing such evidence for large numbers of patients often requires considerable time and...